Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DGCR2 (DiGeorge syndrome critical region gene 2) encodes an integral membrane protein believed to function as a putative adhesion receptor involved in cell-cell and cell-matrix interactions essential for normal cell differentiation and migration. It plays a key developmental role in neural crest cell migration, cardiac and thymic development, and neural circuit formation. Deletions or changes in DGCR2 within the 22q11.2 chromosomal region cause defects seen in DiGeorge syndrome, including congenital heart disease, thymic deficiency, and neuropsychiatric disorders like schizophrenia and intellectual disability. DGCR2 expression has also been mapped to pancreatic β-cells and is a candidate marker for non-invasive diabetes diagnostics. The molecular properties and broad involvement in development make DGCR2 both a potential disease biomarker and a target for future research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DiGeorge syndrome critical region gene 2 (DGCR2).